Gilead Sciences: Another Blow to R&D Strategy
September 22, 2016 at 11:52 AM EDT
Last night, Gilead Sciences ( GILD ) announced that it had halted a trial for an ulcerative colitis treatment . Leerink's Geoffrey Porges and Bradley Canino call it "another blow to [Gilead's] R&D strategy." They explain why:
